Climb Bio (NASDAQ:CLYM) Given Buy Rating at BTIG Research

Climb Bio (NASDAQ:CLYM)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $19.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 80.09% from the company’s previous close.

CLYM has been the topic of several other research reports. B. Riley Financial started coverage on shares of Climb Bio in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Piper Sandler started coverage on shares of Climb Bio in a research report on Friday, February 13th. They issued an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Oppenheimer boosted their price target on shares of Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Climb Bio has an average rating of “Buy” and a consensus target price of $20.30.

Climb Bio Price Performance

Climb Bio stock opened at $10.55 on Monday. The stock has a market cap of $604.12 million, a P/E ratio of -13.53 and a beta of 0.09. Climb Bio has a 1 year low of $1.16 and a 1 year high of $12.48. The firm’s 50 day moving average price is $9.55 and its 200-day moving average price is $6.41.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. As a group, equities analysts expect that Climb Bio will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Climb Bio

Several large investors have recently bought and sold shares of the business. Peapod Lane Capital LLC increased its position in Climb Bio by 0.7% in the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after purchasing an additional 4,126 shares during the last quarter. XTX Topco Ltd boosted its stake in Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after buying an additional 5,668 shares during the period. Virtu Financial LLC purchased a new position in Climb Bio during the fourth quarter worth $43,000. Blair William & Co. IL purchased a new position in Climb Bio during the fourth quarter worth $44,000. Finally, Hsbc Holdings PLC boosted its stake in Climb Bio by 107.2% during the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after buying an additional 12,800 shares during the period. Institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.